Drug Summary Info Document Request / monitor Goal of therapy Action

Slides:



Advertisements
Similar presentations
JOURNAL REVIEW Newer Antithrombotics in AF 1 Dr Ranjith MP Senior Resident Department of Cardiology Government Medical college Kozhikode.
Advertisements

The Changing Landscape of Anticoagulation William D. Cahoon, Jr., PharmD, BCPS Cardiology Clinical Pharmacist VCU Health System April 12, 2012.
Update on the New Oral Anticoagulants
What a Bloody Mess! A/Professor Kent Robinson Senior Staff Specialist, Liverpool & Campbelltown Hospitals.
Newer Anticoagulants Drug Class Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services October 16, 2013.
New Oral Anticoagulants (NOACs) Dabigatran and Rivaroxaban for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation Dr Dipti.
Heparin in CRRT Benan Bayrakci, McLean Antitrombin 3 Inactive Thrombin (IIa) V, VIII, XIII, Fibrinogen Inactive Factor Xa Common Pathway Inactive.
CLINICAL CASES.
DR DIPTI CHITNAVIS HAEMATOLOGY CONSULTANT WEST SUFFOLK HOSPITAL JANUARY 2014 Update on the new oral anticoagulants; 12 months on.
NEW ORAL ANTICOAGULANTS
Preventing Anticoagulation Errors with Clinical Dashboards Dan Johnson, Pharm.D., BCPS August 3, 2011.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
The New Oral Anticoagulants: Handle with Care Philip C. Comp, M.D., Ph.D. October 18, 2013.
Dalia Elfawy., MD Lecturer of Anesthesia and ICU Ain Shams University 2014 RAPID REVERSAL OF ANTICOAGULATION IN TRAUMA PATIENTS.
New oral anticoagulants: an update
Care of the Anti-coagulated Trauma Patient Julie Mayglothling, MD, FACEP Emergencies in Medicine March 8 th, 2012.
Mechanical Clot Detection
Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.
Adam M. Levine, DO, FACC Clinical Assistant Professor of Medicine Rowan University September 12 th, 2015.
 Background  Cost  Benefit  Complication.
Anticoagulants and reversal
Agents Affecting Blood Clotting
Dr. Ryan Clark, DO Grandview Medical Center, Dayton, OH NOVEL ORAL ANTICOAGULANTS.
Novel Anticoagulants (NOACs) in Non Valvular Atrial Fibrillation
Non-vitamin K antagonist oral anticoagulants (NOACs)
Anticoagulation in Atrial Fibrillation Dalia Hawwass PGY2 June 2015.
April 23, 2015 Mini-Lecture Nathan King M.D. Anticoagulation Reversal Part 1: Warfarin.
Non-vitamin K antagonist oral anticoagulants (NOACs) YOUR FACILITY Presenter Month YYYY September 2016 Version 2.
Low Procedural Bleed Risk
An Update on Reversal Agents for NOACs: Where Are We Now?
Warfarin, Your Days are Numbered!
Anticoagulation By Alaina darby.
Desirudin Drugbank ID : DB11095.
Anticoagulants How much, which one & how long?
The management of anti-thrombotics in patients undergoing GI endoscopy
Evidence-Based Management of Anticoagulant Therapy
AUB:Iatrogent Coagulopathy
Fadiea Al-Aieshy   PhD-student, MSc Pharm
You can never be too Thin…. An Update on NOACs
A Challenging Case of Anticoagulant-Related GI Bleeding
Effects of rivaroxaban and apixaban on routine coagulation screening tests Sean Platton1*, Louise Bowles1, Peter MacCallum2 The Royal London Hospital,
Warfarin Toxicity Treatment & Management
Anticoagulants and Antiplatelets
Anticoagulants in the Treatment of Venous Thromboembolism
Management of Direct Oral Anticoagulants
Anticoagulation in chronic liver disease
Ortho Warfarin Dosing Protocol
Anticoagulation in Atrial Fibrillation
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
In the name of God. Management trauma in elderly DR. NIKSOLAT GERIATRICIAN ASSISTANT PROFESSOR, IRAN UNIVERSITY OF MEDICAL SCIENCE.
Anticoagulation Prepared by Cherie Gan.
Click here for title Click here for subtitle
Anticoagulant Review Morning Report – April 25, 2018
Module 3 REDUCE THE LIKELIHOOD OF PATIENT HARM ASSOCIATED WITH THE USE OF ANTICOAGULANT THERAPY.
Reversal of Direct Oral Anticoagulants (DOAC)
“Reversing Direct Oral Anticoagulants”
John Fanikos, RPh, MBA, Allison E. Burnett, PharmD, Charles E
New oral anticoagulants—what the cardiothoracic surgeon needs to know
Direct Oral Anticoagulants
DOACs and Urgent Bleeding
Neurosurgery and DOACs
Oral Anticoagulant Reversal Agents
Anticoagulant Reversal
Periprocedural Management of Patients on Anticoagulation
ONLY oral unit-dose warfarin, prefilled Fragmin syringes, and premixed heparin drips are used at CHSB.
Use of direct oral anticoagulants (DOACs) in primary care
Arman Qamar et al. JACC 2018;71:
Follow-up: considerations
10/28/2019.
Use Fixed low dose Prothrombin Complex Concentrate (Octaplex)
Presentation transcript:

Pre-operative management of anticoagulants in older hip fracture patients Drug Summary Info Document Request / monitor Goal of therapy Action Warfarin Vitamin K antagonist Long half life Metabolised by the liver Document indication, usual dose and time of last dose. INR INR < 1.5 If INR >1.4 & <3.0 – give 3mg IV vitamin K in ED and aim for surgery the following day. If INR >3 – give 5mg IV vitamin K in ED. If INR still >1.4 on day of surgery, give FFP and/or Prothrombinex (via haematology). Dabigitran (Pradaxa) Direct thrombin inhibitor Renally excreted Half life increases with decreasing CrCl (13-27hrs) Document indication, usual dose and time of last dose. TT, APTT and Haemoclot (thrombin inhibitor assay) Normal APTT, normal or mildly prolonged TT and dabigitran level < 50ng/ml Praxbind reverses effects but not used routinely. Calculate creatinine clearance (not eGFR). Surgery likely to be delayed a minimum of 24hrs and more likely 48hrs depending on initial drug level and calculated creatinine clearance. Rivaroxaban / Apixaban Factor Xa inhibitor Partial renal excretion Half life increases with decreasing CrCl (8-13hrs) Document indication, usual dose and time of last dose. Rivaroxaban / apixaban assay (anti Xa assay) Anti Xa assay level < 50ng/ml No agent to reverse effect yet. Calculate creatinine clearance (not eGFR). Surgery likely to be delayed a minimum of 24hrs depending on initial drug level and calculated creatinine clearance. The Orthogeriatric team should be made aware of these patients at the point of admission. In some patients, bridging anticoagulation is required and this may require an additional discussion with haematology or cardiology depending on indication. In cases of active bleeding, please contact the on call haematologist.